You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameQuazepam
Accession NumberDB01589
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionQuazepam is a drug which is a benzodiazepine derivative. It induces impairment of motor function and has hypnotic properties. Quazepam is used to treat insomnia.
Structure
Thumb
Synonyms
Doral
Quazepamum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Doraltablet15 mg/1oralCutis Health, LLC2016-04-12Not applicableUs
Quazepamtablet15 mg/1oralA S Medication Solutions Llc2013-08-08Not applicableUs
Quazepamtablet15 mg/1oralbryant ranch prepack2013-08-08Not applicableUs
Quazepamtablet15 mg/1oralThompson Medical Solutions Llc2016-04-12Not applicableUs
Quazepamtablet15 mg/1oralUnit Dose Services2013-08-08Not applicableUs
Quazepamtablet15 mg/1oralPreferred Pharmaceuticals, Inc.2013-08-152016-01-13Us
Quazepamtablet15 mg/1oralA S Medication Solutions Llc2013-08-08Not applicableUs
Quazepamtablet15 mg/1oralKLE 2, Inc.2013-08-082015-12-29Us
Quazepamtablet15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-08-082016-01-13Us
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DoralNot Available
DormalinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIJF8V0828ZI
CAS number36735-22-5
WeightAverage: 386.794
Monoisotopic: 386.026759579
Chemical FormulaC17H11ClF4N2S
InChI KeyInChIKey=IKMPWMZBZSAONZ-UHFFFAOYSA-N
InChI
InChI=1S/C17H11ClF4N2S/c18-10-5-6-14-12(7-10)16(11-3-1-2-4-13(11)19)23-8-15(25)24(14)9-17(20,21)22/h1-7H,8-9H2
IUPAC Name
7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-1,4-benzodiazepine-2-thione
SMILES
FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=C1C=C(Cl)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Thiolactam
  • Tertiary amine
  • Ketimine
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Imine
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to treat insomnia.
PharmacodynamicsQuazepam is a benzodiazepine derivative. The main pharmacological action of quazepam is the enhancement of the neurotransmitter, GABA at the GABAA receptor.
Mechanism of actionBenzodiazepines bind nonspecifically to benzodiazepine receptors, which affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Related Articles
AbsorptionBioavailability is 29-35% following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half life39 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9385
Blood Brain Barrier+0.9789
Caco-2 permeable+0.5748
P-glycoprotein substrateSubstrate0.5341
P-glycoprotein inhibitor IInhibitor0.9324
P-glycoprotein inhibitor IIInhibitor0.8253
Renal organic cation transporterInhibitor0.6883
CYP450 2C9 substrateNon-substrate0.8255
CYP450 2D6 substrateNon-substrate0.8135
CYP450 3A4 substrateSubstrate0.5133
CYP450 1A2 substrateInhibitor0.7023
CYP450 2C9 inhibitorInhibitor0.5757
CYP450 2D6 inhibitorNon-inhibitor0.6337
CYP450 2C19 inhibitorInhibitor0.688
CYP450 3A4 inhibitorInhibitor0.7937
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9484
Ames testNon AMES toxic0.6683
CarcinogenicityNon-carcinogens0.7273
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9195 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.978
hERG inhibition (predictor II)Inhibitor0.6396
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7608616 No2008-06-032028-06-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point137.5-139 °CPhysProp
logP4.03SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00231 mg/mLALOGPS
logP4.76ALOGPS
logP5.06ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)18.93ChemAxon
pKa (Strongest Basic)2.59ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.6 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity93.47 m3·mol-1ChemAxon
Polarizability33.99 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-05aa-3988000000-ca1cf29da979ef46dd6cView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CD10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Quazepam is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Quazepam can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Quazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Quazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Quazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Quazepam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Quazepam.
AmiodaroneThe metabolism of Quazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Quazepam is combined with Amisulpride.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Quazepam.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Quazepam.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Quazepam.
AmoxapineThe risk or severity of adverse effects can be increased when Quazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Quazepam is combined with Amperozide.
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Quazepam.
AprepitantThe serum concentration of Quazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.
ArmodafinilThe metabolism of Quazepam can be decreased when combined with Armodafinil.
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Quazepam.
ArticaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Quazepam is combined with Asenapine.
AtazanavirThe metabolism of Quazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Quazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Azaperone.
AzelastineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Quazepam.
BaclofenThe risk or severity of adverse effects can be increased when Quazepam is combined with Baclofen.
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Quazepam.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Quazepam.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Quazepam.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Quazepam.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Quazepam.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Quazepam.
BexaroteneThe serum concentration of Quazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Quazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Quazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Quazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Quazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Quazepam.
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Quazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Quazepam.
BrotizolamThe risk or severity of adverse effects can be increased when Quazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Quazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Quazepam.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Quazepam.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Quazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Quazepam.
ButacaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Quazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Quazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Quazepam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Quazepam.
CapecitabineThe metabolism of Quazepam can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Quazepam.
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Quazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Quazepam.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Quazepam.
CarisoprodolThe risk or severity of adverse effects can be increased when Quazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Quazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Quazepam.
ChloramphenicolThe metabolism of Quazepam can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Quazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Quazepam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quazepam.
ChlorphenamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Quazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Quazepam.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Quazepam can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Quazepam can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Quazepam.
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Quazepam.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Quazepam.
CitalopramThe risk or severity of adverse effects can be increased when Quazepam is combined with Citalopram.
CitalopramThe metabolism of Quazepam can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Quazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Quazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Quazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Quazepam is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Quazepam.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Quazepam.
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Quazepam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Quazepam.
ClomipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Clonidine.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Quazepam.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Quazepam.
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Quazepam.
ClotrimazoleThe metabolism of Quazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Quazepam.
CobicistatThe metabolism of Quazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Quazepam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Quazepam.
ConivaptanThe serum concentration of Quazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Quazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Quazepam.
CyclosporineThe metabolism of Quazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Quazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Quazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Quazepam is combined with Dapoxetine.
DarunavirThe metabolism of Quazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Quazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Quazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Quazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Quazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Quazepam.
DesipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Quazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Quazepam.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Quazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Quazepam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Quazepam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Quazepam.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Quazepam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Quazepam.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Quazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Quazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Quazepam.
DihydroergotamineThe metabolism of Quazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Quazepam.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Quazepam.
DiltiazemThe metabolism of Quazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Quazepam is combined with Dimenhydrinate.
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Quazepam.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Quazepam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Quazepam.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Quazepam.
DoramectinThe risk or severity of adverse effects can be increased when Quazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Quazepam is combined with Doxepin.
DoxycyclineThe metabolism of Quazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Quazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
DronedaroneThe metabolism of Quazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Quazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Quazepam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Quazepam.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Quazepam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Quazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Quazepam.
EfavirenzThe serum concentration of Quazepam can be decreased when it is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Quazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Quazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Quazepam can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Quazepam.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Quazepam.
ErythromycinThe metabolism of Quazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Quazepam can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Quazepam can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Quazepam.
EstroneThe serum concentration of Estrone can be increased when it is combined with Quazepam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Quazepam.
EthanolQuazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Quazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Quazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Quazepam.
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Quazepam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Quazepam.
EtidocaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Quazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Quazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Quazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Quazepam.
EtravirineThe serum concentration of Quazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Quazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Quazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Quazepam.
FenfluramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Quazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Quazepam is combined with Flibanserin.
FloxuridineThe metabolism of Quazepam can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Quazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Quazepam.
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Quazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Quazepam.
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Quazepam.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Quazepam.
FluorouracilThe metabolism of Quazepam can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Quazepam.
FluoxetineThe metabolism of Quazepam can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Quazepam.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Quazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Quazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Quazepam can be decreased when combined with Fluvastatin.
FluvoxamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Quazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Quazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Quazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Quazepam is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Quazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Quazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Quazepam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Quazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Quazepam.
GemfibrozilThe metabolism of Quazepam can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Quazepam.
GuanfacineThe risk or severity of adverse effects can be increased when Quazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Quazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.
HalothaneThe serum concentration of Halothane can be increased when it is combined with Quazepam.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Quazepam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Quazepam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Quazepam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quazepam.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Quazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Quazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Quazepam can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Quazepam.
IloperidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Iloperidone.
ImatinibThe metabolism of Quazepam can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Quazepam.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Quazepam.
IndalpineThe risk or severity of adverse effects can be increased when Quazepam is combined with Indalpine.
IndinavirThe metabolism of Quazepam can be decreased when combined with Indinavir.
IrbesartanThe metabolism of Quazepam can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Quazepam.
IsavuconazoniumThe metabolism of Quazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe serum concentration of Isoflurane can be increased when it is combined with Quazepam.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Quazepam.
IsoniazidThe metabolism of Quazepam can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Quazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Quazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Quazepam can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Quazepam.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Quazepam.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Quazepam.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Quazepam.
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Quazepam.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Quazepam.
KetoconazoleThe metabolism of Quazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Quazepam is combined with Lamotrigine.
LeflunomideThe metabolism of Quazepam can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Quazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Quazepam.
LevocabastineThe risk or severity of adverse effects can be increased when Quazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Quazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Quazepam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Quazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Quazepam.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Quazepam.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Quazepam.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Quazepam.
LofentanilThe risk or severity of adverse effects can be increased when Quazepam is combined with Lofentanil.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Quazepam.
LopinavirThe metabolism of Quazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Quazepam.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Quazepam.
LosartanThe metabolism of Quazepam can be decreased when combined with Losartan.
LovastatinThe metabolism of Quazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Quazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Quazepam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Quazepam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Quazepam is combined with Magnesium Sulfate.
MalathionThe serum concentration of Malathion can be increased when it is combined with Quazepam.
MaprotilineThe risk or severity of adverse effects can be increased when Quazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Quazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Quazepam.
MelperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Melperone.
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Quazepam.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Quazepam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Quazepam.
MetaxaloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Quazepam.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Quazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Quazepam.
MethapyrileneThe risk or severity of adverse effects can be increased when Quazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Quazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Quazepam.
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Quazepam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Quazepam.
MethsuximideThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.
MethylphenobarbitalThe serum concentration of Methylphenobarbital can be increased when it is combined with Quazepam.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Quazepam.
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Quazepam.
MetyrosineQuazepam may increase the sedative activities of Metyrosine.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Quazepam.
MianserinThe serum concentration of Mianserin can be increased when it is combined with Quazepam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Quazepam.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Quazepam.
MifepristoneThe metabolism of Quazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Quazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
MirtazapineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Quazepam.
MitotaneThe serum concentration of Quazepam can be decreased when it is combined with Mitotane.
MoclobemideThe metabolism of Quazepam can be decreased when combined with Moclobemide.
ModafinilThe serum concentration of Quazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Quazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.
NabiloneThe risk or severity of adverse effects can be increased when Quazepam is combined with Nabilone.
NafcillinThe serum concentration of Quazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Quazepam.
NefazodoneThe metabolism of Quazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Quazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Quazepam can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Quazepam.
NevirapineThe metabolism of Quazepam can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Quazepam can be decreased when combined with Nicardipine.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Quazepam.
NilotinibThe metabolism of Quazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Quazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Quazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Quazepam is combined with Olanzapine.
OlaparibThe metabolism of Quazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Quazepam is combined with Olopatadine.
OmeprazoleThe metabolism of Quazepam can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Quazepam.
OpiumThe risk or severity of adverse effects can be increased when Quazepam is combined with Opium.
OrphenadrineQuazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Quazepam.
OsanetantThe risk or severity of adverse effects can be increased when Quazepam is combined with Osanetant.
OsimertinibThe serum concentration of Quazepam can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Quazepam.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quazepam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Quazepam.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Quazepam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Quazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Quazepam.
PalbociclibThe serum concentration of Quazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Quazepam.
PantoprazoleThe metabolism of Quazepam can be decreased when combined with Pantoprazole.
ParaldehydeQuazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Quazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Quazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Quazepam.
PerampanelThe risk or severity of adverse effects can be increased when Quazepam is combined with Perampanel.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Quazepam.
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Quazepam.
PerospironeThe risk or severity of adverse effects can be increased when Quazepam is combined with Perospirone.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Quazepam.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Quazepam.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Quazepam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Quazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Quazepam.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Quazepam is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Quazepam is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Quazepam.
PipamperoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Quazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Quazepam can be decreased when combined with Posaconazole.
PramipexoleQuazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Pramocaine.
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Quazepam.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Quazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Quazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Quazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Quazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Quazepam.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Quazepam.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Quazepam.
PropofolThe serum concentration of Propofol can be increased when it is combined with Quazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Quazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Quazepam is combined with PSD502.
PyrimethamineThe metabolism of Quazepam can be decreased when combined with Pyrimethamine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Quazepam.
QuinineThe metabolism of Quazepam can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Quazepam is combined with Ramelteon.
RanolazineThe metabolism of Quazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quazepam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Quazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Quazepam.
RifabutinThe metabolism of Quazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Quazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Quazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Quazepam.
RitonavirThe metabolism of Quazepam can be decreased when combined with Ritonavir.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Quazepam.
RomifidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Romifidine.
RopiniroleQuazepam may increase the sedative activities of Ropinirole.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Quazepam.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Quazepam.
RotigotineQuazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Quazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Quazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Quazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quazepam.
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Quazepam.
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Quazepam.
SertindoleThe risk or severity of adverse effects can be increased when Quazepam is combined with Sertindole.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Quazepam.
SertralineThe metabolism of Quazepam can be decreased when combined with Sertraline.
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Quazepam.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Quazepam.
SildenafilThe metabolism of Quazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Quazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Quazepam can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Quazepam is combined with Sodium oxybate.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Quazepam.
SorafenibThe metabolism of Quazepam can be decreased when combined with Sorafenib.
St. John's WortThe serum concentration of Quazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Quazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.
SulfadiazineThe metabolism of Quazepam can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Quazepam can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Quazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Quazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Quazepam is combined with Suvorexant.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Quazepam.
TapentadolThe risk or severity of adverse effects can be increased when Quazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Quazepam is combined with Tasimelteon.
TelaprevirThe metabolism of Quazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Quazepam can be decreased when combined with Telithromycin.
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Quazepam.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Quazepam.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Quazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Quazepam is combined with Tetrodotoxin.
ThalidomideQuazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Quazepam.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quazepam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Quazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Quazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiagabine.
TicagrelorThe metabolism of Quazepam can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Quazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Quazepam can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Quazepam can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Quazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Quazepam is combined with Topiramate.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Quazepam.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Quazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Quazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Quazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Trazodone.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Quazepam.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Quazepam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Quazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Quazepam.
TrimethoprimThe metabolism of Quazepam can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Quazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Triprolidine.
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Quazepam.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Quazepam.
ValsartanThe metabolism of Quazepam can be decreased when combined with Valsartan.
VenlafaxineThe metabolism of Quazepam can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Quazepam.
VerapamilThe metabolism of Quazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Quazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Quazepam can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Quazepam.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Quazepam.
XylazineThe risk or severity of adverse effects can be increased when Quazepam is combined with Xylazine.
ZafirlukastThe metabolism of Quazepam can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Quazepam.
ZiconotideThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Quazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Quazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Quazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Quazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Quazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Quazepam.
ZotepineThe risk or severity of adverse effects can be increased when Quazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Quazepam is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  4. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Meldrum BS, Chapman AG: Benzodiazepine receptors and their relationship to the treatment of epilepsy. Epilepsia. 1986;27 Suppl 1:S3-13. [PubMed:3017690 ]
  2. Billard W, Crosby G, Iorio L, Chipkin R, Barnett A: Selective affinity of the benzodiazepines quazepam and 2-oxo-quazepam for BZ1 binding site and demonstration of 3H-2-oxo-quazepam as a BZ1 selective radioligand. Life Sci. 1988;42(2):179-87. [PubMed:2892106 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:30 / Updated on September 30, 2016 02:25